Lilly Reports Solid First-Quart...(of foreign exchange rates. Cialis ...)

Cialis

Cialis sales for the first quarter of 2008 were $336.9 million. Worldwide sales of Cialis grew 27 percent compared with first-quarter 2007. U.S. sales of Cialis were $123.0 million in the first quarter, a 25 percent increase compared with the first quarter of 2007, driven by higher prices and increased demand. Sales of Cialis outside the U.S. increased 28 percent, to $214.0 million, driven primarily by higher demand and the favorable impact of foreign exchange rates.

Prior to the acquisition of ICOS on January 29, 2007, Cialis sales in Lilly territories were reported in Lilly's revenue, while Lilly's 50 percent share of the joint-venture territory sales, net of expenses, was reported in Lilly's other income. After the acquisition of ICOS, all Cialis sales are reported in Lilly's revenue.

Evista

Evista sales were $261.1 million in the first quarter of 2008, a 1 percent decrease compared with the first quarter of 2007. U.S. sales of Evista were essentially flat at $171.3 million, as a result of higher prices, offset by lower demand. Sales outside the U.S. decreased 2 percent, to $89.8 million, driven by lower demand and lower prices, partially offset by favorable exchange rates.

Humulin

Worldwide Humulin sales increased 14 percent in the first quarter of 2008, to $257.7 million. U.S. sales increased 9 percent, to $93.1 million, due to higher prices, partially offset by lower demand. Sales outside the U.S. increased 17 percent, to $164.6 million, driven by the favorable impact of foreign exchange rates and increased demand, partially offset by lower prices.

Alimta

For the first quarter of 2008, Alimta generated sales of $247.2 million, an increase of 32 percent compared with the first quarter of 2007. U.S. sales of Alimta increased 17 percent, to $121.9 million, due primarily to increased demand, while sales outside the U.S. increased 50 percent, to $125.3 million, due pri
'/>"/>